Overview
Banked ADMSCs are delivered through two complementary routes: intravenous infusion (systemic) and localized injection (targeted). Each route serves a distinct therapeutic purpose within the same care day.
The science
Systemic infusion
IV infusion distributes mesenchymal stem cells through the bloodstream, where they migrate toward sites of inflammation via chemotactic signaling. This route supports whole-body modulation — particularly relevant for chronic systemic conditions.
Targeted injection
Localized injections deliver concentrated cells directly to damaged tissue (joints, tendons, soft tissue). Targeted delivery maximizes therapeutic concentration where structural repair is needed.
Citations
Stem Cell Infusion
- Chiarotto GB, et al. Delayed onset, immunomodulation, and lifespan improvement of SOD1G93A mice after intravenous injection of human mesenchymal stem cells derived from adipose tissue. Brain Res Bull. 2022. PubMed 35718222 →
- Patel S, et al. A narrative review on the therapeutic potential of stem cells in neurodegenerative diseases: advances, insights, and challenges. Ann Med Surg. 2025. PubMed 41675725 →
Stem Cell Injection
- Wei P, Bao R. Intra-articular mesenchymal stem cell injection for knee osteoarthritis: mechanisms and clinical evidence. Int J Mol Sci. 2022. PubMed 36613502 →
- Lee WS, et al. Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIb, randomized, placebo-controlled clinical trial. Stem Cells Transl Med. 2019. PubMed 30835956 →